Project Details
Description (abstract)
The goal of the 5-year research project is to discover novel diagnostic tools and effective drug combinations based on data from high-grade serous ovarian cancer patients. Partners in this international and multidisciplinary project come from 14 organisations in seven EU countries.
Legal work package addresses the ethical and legal concerns that may arise in the project. Furthermore, the legal researchers will also study whether there are inconsistencies between the pharmaceutical regulatory system and other relevant legislation.
“Our aim is to overcome legal challenges that impede or slow down the provision of new treatments for chemotherapy resistance in high-grade serous ovarian cancer patients. We want to facilitate the commercialisation and availability of personalized therapies in an ethically and legally sustainable manner,” says Professor Päivi Korpisaari.
Legal work package addresses the ethical and legal concerns that may arise in the project. Furthermore, the legal researchers will also study whether there are inconsistencies between the pharmaceutical regulatory system and other relevant legislation.
“Our aim is to overcome legal challenges that impede or slow down the provision of new treatments for chemotherapy resistance in high-grade serous ovarian cancer patients. We want to facilitate the commercialisation and availability of personalized therapies in an ethically and legally sustainable manner,” says Professor Päivi Korpisaari.
| Short title | DECIDER |
|---|---|
| Acronym | DECIDER |
| Status | Active |
| Effective start/end date | 01/02/2021 → 31/01/2026 |